ArticleBMC genomics2025
Whole genome sequencing to characterize the molecular epidemiology and drug-resistance of tuberculosis in Huzhou, China.
Article in BMC genomics, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
Abstract
backgroundWhole-genome sequencing (WGS) has emerged as a powerful tool for elucidating Mycobacterium tuberculosis (MTB) transmission dynamics and drug resistance patterns. In China, the application of WGS in TB surveillance has been rapidly expanding. However, molecular epidemiological studies based on WGS data from low-incidence areas remain limited. Huzhou City, located in northern Zhejiang Province, reported a TB incidence rate of 27.16 per 100,000 population in 2024, which was lower than both the national and provincial averages. In July 2023, Huzhou pioneered China’s first “TB-Free City” initiative. To support public health efforts and facilitate the development of a WGS-based molecular surveillance network tailored for low-incidence settings, we performed WGS on 350 MTB isolates obtained from culture-positive TB patients in Huzhou between March 2023 and September 2024. Phylogenetic analysis, drug resistance profiling, and transmission cluster identification (using a ≤ 12 SNP threshold) were conducted to characterize the molecular epidemiology of TB in this region.
resultsLineage 2.2.1 (Beijing genotype) was predominant (80.0%). A total of 86 isolates (24.6%) harbored drug resistance-associated mutations, including 2.0% MDR-TB and 1.7% pre-XDR-TB, with no XDR-TB or resistance to bedaquiline, linezolid, or delamanid detected. We identified 28 genomic clusters comprising 65 isolates (18.6%), with a clustering rate of 11.6% among DR-TB cases. Furthermore, 79.1% (68/86) of drug-resistant TB (DR-TB) cases were likely attributable to recent transmission, with clustered DR-TB strains sharing identical resistance-conferring mutations. Comparative analysis revealed that patients under 60 years of age were significantly more likely to be involved in recent transmission events (P = 0.035), while lineage, gender, occupation, treatment history, and local residency were not statistically associated with clustering.
conclusionsOur findings suggest that recent transmission, particularly among younger individuals, contributes substantially to the DR-TB burden in Huzhou. WGS-based surveillance revealed moderate resistance levels and limited transmission, supporting the ongoing “TB-Free City” initiative. Enhanced genomic monitoring and early intervention targeting younger, mobile populations may further curb TB transmission in low-incidence settings.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.